This page shows the latest asthma news and features for those working in and with pharma, biotech and healthcare.
The company has already created AI tools for heart failure, chronic obstructive pulmonary disease, asthma and acute respiratory illness.
This is partly due to an age-related decline in immunity. RSV can also exacerbate other conditions, including chronic obstructive pulmonary disease, asthma, and chronic heart failure.
The inflammatory skin disease affects an estimated 16.5 million adults in the US
This is partly due to age-related decline in immunity. RSV can also exacerbate other conditions, including chronic obstructive pulmonary disease, asthma and chronic heart failure.
This is partly due to age-related decline in immunity. RSV can also exacerbate other conditions, including chronic obstructive pulmonary disease, asthma and chronic heart failure.
This is partly due to age-related decline in immunity. RSV can also exacerbate other conditions, including chronic obstructive pulmonary disease, asthma and chronic heart failure.
More from news
Approximately 80 fully matching, plus 517 partially matching documents found.
Write a ‘day in the life’ diary for a patient with severe asthma.
Bronchiectasis is the third largest chronic respiratory disease after asthma and COPD and it affects over 300, 000 people across the UK and causes an estimated 1, 500 deaths each year.
As a company working towards this promise, we are active in a range of therapy areas including reproductive health, heart disease, dermatology, allergies and asthma.
By Max Noble. Patients, or should we say people, with conditions such as asthma, rheumatoid arthritis and lupus have never had as much access to medical information as they do today.
In asthma it is down at around 50% and even in oncology the compliance figures are shocking.
More from intelligence
Approximately 3 fully matching, plus 55 partially matching documents found.
inflammation test for managing asthma, across key markets such as the United States, China, and Japan, as well as the rest of the world.
company's first respiratory biologic for severe asthma.
In his new role, Dr Ford will oversee the development of the company's novel muco-regulatory therapies for patients suffering with chronic obstructive pulmonary disease, cystic fibrosis and severe asthma.
the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.
Most recently these saw him serve as VP and medicines development leader responsible for the late-stage development of once-daily inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD).
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
From Davina McCall’s Sex, Myths and the Menopause documentary to the latest research pointing to asthma treatments failing female suffers, a momentum has started to better highlight the male skew
There was also a greater number of generic products. Anticoagulant therapies such as apixaban, rivaroxaban and edoxaban topped the spending charts, while respiratory products such as inhalable treatments for asthma and
Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma. ... Head of “Living With”, Mariel Metcalfe, discusses the nature of severe asthma and severe eosinophilic asthma, and some key findings from recent studies
Boehringer Ingelheim recently introduced the first reusable, propellant-free inhaler for patients with asthma and COPD, supporting objectives of carbon and plastic waste reduction.
For example, with long term conditions such as asthma and diabetes, remote monitoring enables better self-management, which in turn, should lead to fewer hospital admissions, less face-to-face contact
More from PMHub
Approximately 3 fully matching, plus 18 partially matching documents found.
No results were found
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...